



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/552,194	10/12/2006	Matthew A. Nugent	701586-53702	8409		
50607	7590	04/28/2008	EXAMINER			
RONALD I. EISENSTEIN 100 SUMMER STREET NIXON PEABODY LLP BOSTON, MA 02110				UNDERDAHL, THANE E		
ART UNIT		PAPER NUMBER				
1651						
MAIL DATE		DELIVERY MODE				
04/28/2008		PAPER				

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10552194	10/12/2006	NUGENT ET AL.	701586-53702

EXAMINER

THANE UNDERDAHL

ART UNIT	PAPER
----------	-------

1651 20080422

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

Commissioner for Patents

**Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below. **All sequences disclosed in the application must comply with the requirements of 37 C.F.R. 1.821-1.825, not only those recited in the claims.**

Specifically claim 11 is to SEQ ID NO:1 but no corresponding sequence has been received by the office. Searching this invention and thus examination is not possible until such sequence is received.

All such sequences are relevant for the purposes of building a comprehensive database and properly assessing prior art. It is therefore essential that all sequences, whether only disclosed or also claimed, be included in the database.

Applicant is given **ONE MONTH**, or **THIRTY DAYS**, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the **SIX MONTH** statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

**Please note that examination cannot continue unless the sequence compliance rule requirements are fulfilled.** The applicant should carefully review the specification for any other sequences, in order to avoid necessitating a second Notice To Comply and hindering prosecution.

/Leon B Lankford Jr/  
Primary Examiner, Art Unit 1651